EL
Therapeutic Areas
Teva Pharmaceutical Industries Pipeline
| Drug | Indication | Phase |
|---|---|---|
| PONLIMSI™ (denosumab-adet) | Biosimilar to Xgeva®/Prolia® (osteoporosis, bone metastases) | Approved |
| Biosimilar to Xolair® (omalizumab) | Asthma, Chronic Spontaneous Urticaria | Under Regulatory Review |
| Biosimilar to Simponi® (golimumab) | Rheumatoid Arthritis, Psoriatic Arthritis | Clinical |
| Novel Immunology Candidate | Ulcerative Colitis, Crohn's Disease | Phase 3 |
| Novel Neuroscience Candidate | Multiple System Atrophy (MSA) | Phase 2 |
| Novel Immuno-Oncology Candidate | Attenukine Oncology | Phase 1 |
Leadership Team at Teva Pharmaceutical Industries
RF
Richard Francis
President and Chief Executive Officer
DE
Dr. Eric Hughes
Executive Vice President, Global R&D and Chief Medical Officer
EL
Evan Lippman
Executive Vice President, Business Development
SD
Sven Dethlefs
Executive Vice President, Global Marketing & Access